← FDA DRUG APPROVALS

FDA ANDA · ANDA075525

FLUOXETINE

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA075525
TYPE
ANDA
ORIGINAL APPROVAL
2002-06-27
LATEST ACTION
2025-05-05
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

FLUOXETINE HYDROCHLORIDEPrescription
FLUOXETINE HYDROCHLORIDE EQ 20MG BASE/5ML · SOLUTION · ORAL

Approval history

2025-05-05Manufacturing (CMC) · Supplement 7 · unknownAP
2021-09-20Labeling · Supplement 6 · standardAP
2021-08-31Labeling · Supplement 4 · standardAP
2017-01-04Labeling · Supplement 3 · standardAP
2016-12-27Labeling · Supplement 2 · standardAP
2014-09-11Labeling · Supplement 1 · standardAP
2002-06-27OriginalOther Important Information from FDAAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →